Bone turnover and type I collagen C-telopeptide isomerization in adult osteogenesis imperfecta: Associations with collagen gene mutations

Bone

Volumn 44, Issue 3, 2009, Pages 461-466

  Garnero, Patrick ^a,b   Schott, Anne Marie ^c   Prockop, Darwin ^d   Chevrel, Guillaume ^e  

^a INSERM   (France)

^b Synarc   (France)

^c HOSPICES CIVILS DE LYON   (France)

^d TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^e EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Bone quality; Bone turnover markers; Collagen; Isomerization; Osteogenesis imperfecta

Indexed keywords

CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; PLACEBO;

ADULT; ARTICLE; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; OSTEOGENESIS IMPERFECTA; RANDOMIZED CONTROLLED TRIAL; URINALYSIS;

ADULT; AMINO ACID SEQUENCE; BIOLOGICAL MARKERS; BONE AND BONES; COLLAGEN; COLLAGEN TYPE I; CROSS-SECTIONAL STUDIES; FEMALE; FRACTURES, BONE; HUMANS; ISOMERISM; MALE; MOLECULAR STRUCTURE; MUTATION; OSTEOGENESIS IMPERFECTA; PEPTIDES; PROTEIN CONFORMATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 59649092309     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2008.11.006     Document Type: Article

References (39)

1. Sillence D.O., Senn A., and Danks D.M. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 16 (1979) 101-116
2. Rauch F., and Glorieux F.H. Osteogenesis imperfecta. Lancet 63 (2004) 1377-1385
3. Sykes B., Ogilvie D., Wordsworth P., Wallis G., Mathew C., Beighton P., et al. Consistent linkage of dominantly inherited osteogenesis imperfecta to the type I collagen loci: COL 1A1 and COL 1A2. Am J Hum Genet 46 (1990) 293-307
4. Marini J.C., Forlino A., Cabral W.A., Barnes A.M., San Antonio J.D., Milgrom S., et al. Consortium for osteogenesis imperfecta mutations in the helical domain of type I collagen: regions rich in lethal mutations align with collagen binding sites for integrins and proteoglycans. Hum Mutat 28 (2007) 209-221
5. Brenner R.E., Schiller B., Vetter U., Ittner J., and Teller V.M. Serum concentrations of procollagen I C terminal propeptide, osteocalcin and insulin-like growth factor-I in patients with non-lethal osteogenesis imperfecta. Acta Pediatr 82 (1993) 764-767
6. Minisola S., Piccioni A.L., Rosso R., Romagnoli E., Paciti M.T., Scarnecchia L., et al. Reduced serum levels of carboxy-terminal propeptide of human type I procollagen in a family with type I osteogenesis imperfecta. Metabolism 43 (1994) 1261-1265
7. Currey J.D. The mechanical consequences of variation in the mineral content of bone. J Biochem 2 (1969) 1-11
8. Burr D.B. The contribution of the organic matrix to bone's material properties. Bone 31 (2002) 8-11
9. Currey J.D. Role of collagen and other organics in the mechanical properties of bone. Osteoporos Int 14 suppl 5 (2003) S29-S36
10. Oxlund H., Barckman M., Ortoff G., and Andreassen T.T. Reduced concentrations of collagen crosslinks are associated with reduced strength of bone. Bone 17 (1995) 365S-371S
11. Viguet-Carrin S., Garnero P., and Delmas P.D. The role of collagen in bone strength. Osteoporos Int 17 (2006) 3179-3336
12. Wang X., Shen X., Li X., and Agrawal C.M. Age-related changes in collagen network and toughness of bone. Bone 31 (2002) 1-7
13. Hernandez C.J., Tang S., Baumbach B.M., Hwu P.B., Sakkee A.N., van der Ham F., et al. Trabecular microfracture and the influence of pyridinium and non-enzymatic glycation-mediated collagen cross-links. Bone 37 (2005) 825-832
14. Viguet-Carrin S., Roux J.P., Arlot M.E., Merabet Z., Leeming D.J., Byrjalsen I., et al. Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae. Bone 39 (2006) 1073-1079
15. Garnero P., Borel O., Gineyts E., Duboeuf F., Solberg H., Bouxsein M.L., et al. Extracellular post-translational modifications of collagen are major determinants of biomechanical properties of fetal bovine cortical bone. Bone 38 (2006) 300-309
16. Kirsch E., Krieg T., Remberger K., Fendel H., Bruckener P., and Muller P.K. Disorder of collagen metabolism in patients with osteogenesis imperfecta (lethal type). Increased degree of hydroxylation of lysine in type I and III. Eur J Clin Invest 11 (1981) 39-47
17. Bank R.A., Tekoppele J.M., Janus G.J.M., Wassen M.H.M., Pruijs H.E.H., van der Sluijs H.A.H., et al. Pyridinium cross-links in bone of patients with osteogenesis imperfecta: evidence of a normal intrafibrillar collagen packing. J Bone Miner Res 15 (2000) 1330-1336
18. Garnero P., and Delmas P.D. An immunoassay for type I collagen alpha 1 helicoidal peptide 620-633, a new marker of bone resorption in osteoporosis. Bone 32 (2003) 20-21
19. Garnero P., Cloos P., Sornay-Rendu E., Qvist P., and Delmas P.D. Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the Ofely study. J Bone Miner Res 17 (2002) 826-833
20. Chevrel G., Schott A.M., Fontanges E., Charrin J.E., Lina-Granade G., Duboeuf F., et al. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. J Bone Miner Res 21 (2006) 300-306
21. Carter C.O., and Wilkinson J.A. Genetic and environmental factors in the etiology of congenital dislocation of the hip. Clin Orthop 33 (1964) 119-128
22. Bonde M., Fledelius C., Qvist P., and Christiansen C. Coated tube radioimmunoassay for C-telopeptide to assess bone resorption. Clin Chem 42 (1996) 1639-1644
23. Garnero P., Fledelius C., Gineyts E., Serre C.M., Vignot E., and Delmas P.D. Decreased β isomerization of the C-terminal telopeptide of type I collagen 1 chain in Paget's Disease of bone. J Bone Miner Res 12 (1997) 1407-1415
24. Bonde M., Qvist P., Fledelius C., Riis B.J., and Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 40 (1994) 2022-2025
25. Fledelius C., Johnsen A.H., Cloos P., Bonde M., and Qvist P. Characterization of urinary degradation products derived from type I collagen: identification of a β-isomerized aspartyl residue within the C-telopeptide (α1) region. J Biol Chem 272 (1997) 9755-9763
26. Garnero P., Borel O., and Delmas P.D. Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis. Clin Chem 47 (2001) 694-702
27. Genovese C., and Rowe D. Analysis of cytoplasma and nuclear messenger RNA in fibroblasts from patients with osteogenesis imperfecta. Methods Enzymol 145 (1987) 223-235
28. Willing M.S., Deschenes S.P., Scott D.A., Byers P.H., Slayton R.L., Pitts S.H., et al. Osteogenesis imperfecta type I: molecular heterogeneity for COL1A1 null alleles of type I collagen. Am J Genet 55 (1994) 638-647
29. Prockop D.J., and Kivirikko K.I. Heritable diseases of collagen. N Engl J Med 311 (1984) 376-386
30. Kuivaniemi H., Tromp G., and Prockop D.J. Mutations in fibrillar collagens (types I, II, III and IX), fibril associated collagen (type IX) and network-forming collagen (type X) cause a spectrum of diseases of bone, cartilage and blood vessels. Human Mutat 9 (1997) 300-315
31. Cepollaro C., Gonnelli S., Pondrelli C., Montagnani A., Martinin S., Bruni D., et al. Osteogenesis imperfecta: bone turnover, bone density and ultrasound parameters. Calcif Tissue Int 65 (1999) 129-132
32. Cundy T., Horne A., Bolland M., Gamble G., and Davidson J. Bone formation markers in adults with mild osteogenesis imperfecta. Clin Chem 59 (2007) 1109-1114
33. Lund A.M., Hansen M., Kolerup G., Juul A., Teisner B., and Skovby F. Collagen derived markers of bone metabolism in osteogenesis imperfecta. Acta Paediatr 87 (1998) 1131-1137
34. Braga V., Gatti D., Rossini M., Colapietro F., Battaglia E., Viapiana O., et al. Bone turnover markers in patients with osteogenesis imperfecta. Bone 34 (2004) 1013-1016
35. Brenner R.E., Vetter U., Bollen A.M., Morike M., and Eyre D.R. Bone resorption assessed by immunoassay of urinary cross-linked collagen peptides in patients with osteogenesis imperfecta. J Bone Miner Res 9 (1994) 993-997
36. Rauch F., Travers R., Parfitt A.M., and Glorieux F.H. Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. Bone 35 (2004) 224-230
37. Merle B., and Delmas P.D. Normal carboxylation of circulating osteocalcin (bone Gla-protein) in Paget's disease of bone. Bone Miner 11 (1990) 237-245
38. Alexandersen P., Peris P., Guanabens N., Byrijalsen I., Alvarez L., Solberg H., and Closs P.A. Non-isomerized C-telopeptide fragments are highly sensitive markers for monitoring disease activity and treatment efficacy in Paget's disease of bone. J Bone Miner Res 20 (2005) 588-595
39. Ivaska K.K., Gerdhem P., Akesson K., Garnero P., and Obrant K.J. The effect of fracture on bone turnover markers: a longitudinal study comparing marker levels before and after injury in 113 elderly women. J Bone Miner Res 8 (2007) 1155-1164